medigraphic.com
ISSN 1729-519X (Print)

2019, Number 1

<< Back Next >>

Revista Habanera de Ciencias Médicas 2019; 18 (1)

Type 2 Diabetes mellitus and chemotherapy toxicity in older adults with prostate cancer

Runzer-Colmenares FM, Chambergo-Michilot D, Espinoza-Gutiérrez GA, Corcuera-Ciudad R, Patiño-Villena AF, Paima-Olivari R, Luján PMG, Cabrera-López M, Parodi JF

Language: Spanish
References: 28
Page: 74-87
PDF size: 625.22 Kb.


ABSTRACT

Introduction: Prostate cancer is considered a predominant type of neoplasia and aging is a factor for chemotherapeutic toxicity, which can increase due to chronic diseases, particularly diabetes. Despite all this knowledge, there are no studies to evaluate the association between diabetes and the risk of chemotherapeutic toxicity in these patients.
Objective: To determine the association between Type 2 Diabetes Mellitus and the risk of chemotherapy toxicity in in older adults with prostate cancer in the Geriatric Service of the Peruvian Naval Medical Center.
Material and methods: Analytical retrospective cohort study and secondary database analysis. The adverse effects of chemotherapy and the associated factors of 161 retired sailors with prostate cancer were evaluated between 2013 and 2015. Cox Regression Model for Adjusted Toxicity was constructed for antecedents of diabetes, age, pathological antecedents, smoking antecedents, calf circumference, physical activity, dependence on ABVD, falls, polypharmacy, fragility, and vulnerability.
Results: The 23.6% of patients had diabetes. The prevalence of fragility was 39.7% and the one of vulnerability was 24.2% (G8) and 26.71% (VES- 13). The frequent adverse effects were: gastrointestinal (13.04%) and hematological (8.07%). The most significant associations by adjusted regression model were the antecedent of Type 2 Diabetes Mellitus, 3 or more pathological antecedents, smoking antecedents, calf circumference, physical activity, dependence on ABVD, falls, polypharmacy, fragility, and vulnerability.
Conclusions: The antecedent of Type 2 Diabetes Mellitus is a predictive factor for the risk of chemotherapy toxicity in older adults with prostate cancer.


REFERENCES

  1. Heidenreich A, Bastian P, Bellmunt J, Bolla M, Joniau S, Van Der Kwast T et al. EAU Guidelines on Porstate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent-Update 2013. European Urology [Internet]. 2014 [cited: 3/11/2018];65(1):124-137. Available from: Available from: https://www.europeanurology.com/article/S0302-2838(13)01040-3/fulltext [ Links ]

  2. Heidenreich A, Bastian P, Bellmunt J, Bolla M, Joniau S, Van Der Kwast T et al. EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced Relapsing, and Castration-Resistant Prostate Cancer. European Urology [Internet]. 2014 [cited: 3/11/2018]; 65(2): 467-479. Available from:Available from:https://www.europeanurology.com/article/S0302-2838(13)01199-8/fulltext [ Links ]

  3. Nieuweboer AS, de Morrée EM, de Graan A, Sparreboom A, De Wit R, Mathijssen R. Inter-patient variability in docetaxel pharmacokinetics: A review. Cancer Treat Rev [Internet]. 2015[cited: 3/11/2018]; 41(7):605-613. Available from: Available from: https://www.sciencedirect.com/science/article/pii/S030573721500081X [ Links ]

  4. Burris H, Irvin R, Kuhn J, Kalter S, Smith L, Shaffer D et al. Phase I clinical trial of taxotere administered as either a 2-hour or 6-hour intravenous infusion. J Clin Oncol [Internet]. 1993 [cited: 3/11/2018]; 11(5):950-958. Available from: Available from: http://ascopubs.org/doi/abs/10.1200/JCO.1993.11.5.950 [ Links ]

  5. Klepin H, Pitcher B, Ballman K, Kornblitch A, Hurria A, Winer E. Comorbidity, Chemotherapy Toxicity, and Outcomes Among Older Women Receiving Adjuvant Chemotherapy for Breast Cancer on a Clinical Trial: CALGB 49907 and CALGB 361004 (Alliance). J Oncol Pract [Internet]. 2014 [cited: 3/11/2018]; 10(5):e285-e292. Available from: Available from: http://ascopubs.org/doi/abs/10.1200/jop.2014.001388 [ Links ]

  6. Kalyani R, Corriere M, Ferrucci L. Age-related and disease-related muscle loss: the effect of diabetes, obesity, and other diseases. The Lancet Diabetes & Endocrinology [Internet]. 2014[cited: 3/11/2018]; 2(10):819-829. Available from: Available from: https://www.sciencedirect.com/science/article/pii/S2213858714700348 [ Links ]

  7. Tsilidis K, Kasimis K, Lopez D, Ntzani E, Ioannidis J. Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. Bmj [Internet]. 2015 [cited: 3/11/2018];350:7607. Available from: Available from: https://www.bmj.com/content/350/bmj.g7607 [ Links ]

  8. Runzer-Colmenares FM, Urrunaga-Pastor D, Aguirre LG, Reategui-Rivera CM, Parodi JF, Taype-Rondan A. Fragilidad y vulnerabilidad como predictores de radiotoxicidad en adultos mayores: un estudio longitudinal en Perú. Med Clin [Internet]. 2017[cited: 3/11/2018]; 149(8):325-330. Available from: Available from: https://www.sciencedirect.com/science/article/pii/S0025775317301860 [ Links ]

  9. National Cancer Institute. [Internet]. EU: NIH Publication.; 2017 Common Terminology Criteria for Adverse Events (CTCAE), v5.0.. [cited: 3/11/2018]; Available from: Available from: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm#ctc_40 [ Links ]

  10. Lilamand M, Kelaiditi E, Cesari M, Raynaud-Simon A, Ghisolfi A, Guyonnet S et al. Validation of the Mini Nutritional Assessment-Short Form in a population of frail elders without disability. Analysis of the Toulouse Frailty Platform population in 2013. J Nutr Health Aging [Internet]. 2015[cited: 3/11/2018]; 19(5):570-574. Available from: Available from: https://link.springer.com/article/10.1007/s12603-015-0457-4 [ Links ]

  11. Arnadottir S. Physical Activity Scale for the Elderly (PASE) to capture habitual physical activity patterns of older clients receiving health promoting visits. Physiotherapy [Internet]. 2016 [cited: 3/11/2018]; 102:e208. Available from: Available from: https://www.physiotherapyjournal.com/article/S0031-9406(16)30328-5/abstract [ Links ]

  12. Collin C, Wade DT, Davies S, Horne V. The Barthel ADL Index: a reliability study. Int Disabil Studies [Internet]. 1988. [cited: 3/11/2018]; 10:61-63. Available from: Available from: https://www.tandfonline.com/doi/abs/10.3109/09638288809164103 [ Links ]

  13. Wastesson J, Cedazo A, Fastbom J, Maioli S, Johnell K. The composition of polypharmacy: A registerbased study of Swedes aged 75 years and older. PloS one [Internet]. 2018 [cited: 3/11/2018]; 13(3):e0194892. Available from: Available from: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0194892 [ Links ]

  14. Fried LP, Tangen C, Walston J, Newman A, Hirsch C, Gottdiener J et al. Frailty in Older Adults: Evidence for a Phenotype. J Gerontol Series A: Biological Sciences and Medical Sciences [Internet]. 2001[cited: 3/11/2018]; 56(3):M146-M157. Available from: Available from: https://academic.oup.com/biomedgerontology/article/56/3/M146/545770 [ Links ]

  15. Luciani A, Biganzoli L, Colloca G, Falci C, Castagneto B, Floriani I et al. Estimating the risk of chemotherapy toxicity in older patients with cancer: The role of the Vulnerable Elders Survey-13 (VES-13). J Geriatr Oncol [Internet]. 2015 [cited: 3/11/2018];6(4):272-279. Available from: Available from: https://www.sciencedirect.com/science/article/pii/S1879406815000521 [ Links ]

  16. Kanesvaran R, Zi-Ling O, Chan A, Krishna L, Tan T, Rajasekaran T et al. 539P The use of G8 as a screening tool in a tertiary Asian cancer centre. Ann Oncol [Internet]. 2016[cited: 3/11/2018]; 27(9). Available from: Available from: https://academic.oup.com/annonc/article/27/suppl_9/mdw599.018/2920096 [ Links ]

  17. Fraenkel M, Ketzinel-Gilad M, Ariav Y, Pappo O, Karaca M, Castel J et al. mTOR Inhibition by Rapamycin Prevents β-Cell Adaptation to Hyperglycemia and Exacerbates the Metabolic State in Type 2 Diabetes. Diabetes [Internet]. 2008[cited: 3/11/2018]; 57(4):945-957. Available from: Available from: http://diabetes.diabetesjournals.org/content/57/4/945.short [ Links ]

  18. Tannock I, De Wit R, Berry W, Horti J, Pluzanska A, Oudard S et al. Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer. N Engl J Med [Internet]. 2004[cited: 3/11/2018]; 351(15):1502-1512. Available from: Available from: https://www.nejm.org/doi/full/10.1056/nejmoa040720 [ Links ]

  19. Du Y, Rayner C, Jones K, Talley N, Horowitz M. Gastrointestinal Symptoms in diabetes: prevalence, assessment, pathogenesis, and management. Diabetes Care [Internet]. 2018 [cited: 3/11/2018]; 41(3):627-637. Available from: Available from: http://care.diabetesjournals.org/content/41/3/627 [ Links ]

  20. Lutz S, Hennenlotter J, Scharpf M, Sailer C, Fritsche L, Schmid V et al. Androgen receptor overexpression in prostate cancer in type 2 diabetes. Molecular Metabolism [Internet]. 2018[cited: 3/11/2018]; 8:158-166. Available from: Available from: https://www.sciencedirect.com/science/article/pii/S2212877817306841 [ Links ]

  21. Abizanda P, Romero L, Sanchez-Jurado PM, Martinez-Reig M, Alfonso-Silguero SA, Rodriguez-Manas L. Age, frailty, disability, institutionalization, multimorbidity or comorbidity. Which are the main targets in older adults? The Journal of Nutrition, Health & Aging [Internet]. 2014[cited: 3/11/2018]; 18(6):622. Available from: Available from: https://link.springer.com/article/10.1007/s12603-014-0033-3 [ Links ]

  22. Bechis SK, Carroll PR, Cooperberg MR. Impact of Age at Diagnosis on Prostate Cancer Treatment and Survival. J Clin Oncol [Internet]. 2011[cited: 3/11/2018];29(2):235-241. Available from: Available from: http://ascopubs.org/doi/full/10.1200/JCO.2010.30.2075 [ Links ]

  23. Thompson IM, Ankerst DP, Chi C, Goodman P, Tangen C, Scott M et al. Assessing Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial. JNCI J Natl Cancer Inst [Internet]. 2006[cited: 3/11/2018]; 98(8):529-534. Available from: Available from: https://academic.oup.com/jnci/article/98/8/529/2522069 [ Links ]

  24. Menon A, Handattu S, Shetty J, Shanmukha B. Study of cutaneous adverse effects of cancer chemotherapy. Clin Dermatol Rev [Internet]. 2018[cited: 3/11/2018]; 2(1):19. Available from: Available from: http://www.cdriadvlkn.org/article.asp?issn=2542-551X;year=2018;volume=2;issue=1;spage=19;epage=24;aulast=Menon [ Links ]

  25. Galbraith G, Pandey J. Tumor necrosis factor alpha (TNF-α) gene polymorphism in alopecia areata. Human Genetics [Internet]. 1995[cited: 3/11/2018];96(4):433-436. Available from: Available from: https://link.springer.com/article/10.1007/BF00191802 [ Links ]

  26. Gosney M. Clinical assessment of elderly people with cancer. The Lancet Oncology [Internet]. 2005[cited: 3/11/2018]; 6(10):790-797. Available from: Available from: https://www.sciencedirect.com/science/article/pii/S1470204505703892 [ Links ]

  27. Angulo J, El Assar M, Rodríguez-Mañas L. Frailty and sarcopenia as the basis for the phenotypic manifestation of chronic diseases in older adults. Mol Aspects Med [Internet]. 2016[cited: 3/11/2018]; 50:1-32. Available from: Available from: https://www.sciencedirect.com/science/article/pii/S0098299716300097 [ Links ]

  28. Decoster L, Van Puyvelde K, Mohile S, Wedding U, Basso U, Colloca G et al. Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations. Ann Oncol [Internet]. 2014[cited: 3/11/2018]; 26(2):288-300. Available from: Available from: https://academic.oup.com/annonc/article/26/2/288/2800578 [ Links ]




2020     |     www.medigraphic.com